Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with other agents for MM treatment. Daratumumab is though...

Descripción completa

Detalles Bibliográficos
Autores principales: Naicker, Serika D, Feerick, Claire L, Lynch, Kevin, Swan, Dawn, McEllistrim, Cian, Henderson, Robert, Leonard, Niamh A, Treacy, Oliver, Natoni, Alessandro, Rigalou, Athina, Cabral, Joana, Chiu, Christopher, Sasser, Kate, Ritter, Thomas, O’Dwyer, Michael, Ryan, Aideen E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849715/
https://www.ncbi.nlm.nih.gov/pubmed/33552684
http://dx.doi.org/10.1080/2162402X.2020.1859263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849715/
https://www.ncbi.nlm.nih.gov/pubmed/33552684
http://dx.doi.org/10.1080/2162402X.2020.1859263

Ejemplares similares